Skip to main content
2023 IKCS: North America Main banner
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back
Video

Track: CME Session

SESSION 4: The Story of Belzutifan: Understanding the Drug Development Pathway

Friday, November 10, 2023
12:00 PM – 12:55 PM CST

    Moderator(s)

  • Jodi Maranchie, MD

    University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania, United States

    Disclosure(s): clinical trial support to institution: Jannsen (Ongoing)
    clinical trials support to institution: Merck (Ongoing)

    • Speaker(s)

  • Jaleh Fallah, MD

    Food & Drug Administration
    North Potomac, Maryland, United States

    Disclosure(s): No financial relationships to disclose

    Slides

  • Eric Jonasch, MD

    University of Texas MD Anderson Cancer Center, Texas, United States

    Disclosure(s): Contract Research: Arrowhead Pharmaceuticals (Ongoing); Aveo (Ongoing); Corvus Pharmaceuticals (Ongoing); Merck (Ongoing); NiKang Therapeutics (Ongoing); Telix (Ongoing)
    Non-CE Consulting: Aveo (Ongoing); Eisai (Ongoing); Exelixis (Ongoing); Ipsen (Ongoing); Merck (Ongoing); NiKang Therapeutics (Ongoing); Novartis (Ongoing); Telix (Ongoing)

    Slides
  • RP

    Rodolfo Perini, MD

    Merck Sharpe and Dohme
    North Wales, PA, United States

    Disclosure(s): Ownership Interest: I own stocks of the Commercial entity: Merck & Co. Inc. (Ongoing)
    Salary or Employment Relationship (does not included small non-employed consulting arrangements): Merck & Co. Inc. (Ongoing)

  • Bruce Posner, Ph.D.

    U.T. Southwestern Medical Center
    U.T. Southwestern Medical Center
    Dallas, Texas, United States

    Disclosure information not submitted.

    Slides

  • Naseem Zojwalla, MD

    Olema Oncology
    San Francisco, California, United States

    Disclosure(s): Ownership Interest: I have received future stock options from the Commercial entity: Arcus Oncology (Ongoing); Olema Oncology (Ongoing)
    Ownership Interest: I own stocks of the Commercial entity: Arcus Oncology (Ongoing); Olema Oncology (Ongoing)
    Royalty: Peloton Therapeutics (Ongoing)
    Salary or Employment Relationship (does not included small non-employed consulting arrangements): Olema Oncology (Ongoing)

Presentations:

  • 12:01 PM – 12:13 PM CST
    The Pre-Clinical Story of Belzutifan: From Basic Research Insight to Clinical Candidate

    Speaker: Bruce A. Posner, Ph.D. – U.T. Southwestern Medical Center

  • 12:13 PM – 12:25 PM CST
    IND Package and Early Clinical Development

    Speaker: Eric Jonasch, MD – University of Texas MD Anderson Cancer Center

  • 12:25 PM – 12:37 PM CST
    FDA Evaluation of Data and Approval for Belzutifan

    Speaker: Jaleh Fallah, MD – Food & Drug Administration

  • 12:37 PM – 12:55 PM CST
    Reflections on Drug Development Pathway

    Moderator: Jodi Maranchie, MD – University of Pittsburgh Medical Center

    Speaker: Naseem Zojwalla, MD – Olema Oncology

    Speaker: Rodolfo F. Perini, MD – Merck Sharpe and Dohme